NASDAQ
09.12.24
21:59 Uhr
17,480 US-Dollar
0,000
0,00 %
0,00 %
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Arcus Biosciences' Chefbuchhalter verkauft Aktien im Wert von 3.079 US-Dollar | 3 | Investing.com Deutsch | ||
| 07.11. | Arcus Biosciences Inc reports results for the quarter ended in September 30 - Earnings Summary | 4 | Reuters | ||
| 07.11. | Arcus Biosciences GAAP EPS of -$1.00 beats by $0.04, revenue of $48M beats by $9.05M | 1 | Seeking Alpha | ||
| 06.11. | Arcus Biosciences Reports Third-Quarter 2024 Financial Results and Provides a Pipeline Update | 49 | Business Wire |
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies... ► Artikel lesen | |
| ARCUS BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 06.11. | Arcus Biosciences, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 06.11. | Arcus Biosciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 06.11. | Expert Outlook: Arcus Biosciences Through The Eyes Of 8 Analysts | 1 | Benzinga.com | ||
| 25.10. | Arcus Biosciences (NYSE:RCUS) Trading Down 5.3% - Should You Sell? | 3 | MarketBeat | ||
| 24.10. | Arcus Biosciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 24.10. | Citi raises Arcus Biosciences target to $46, maintains buy | 3 | Investing.com | ||
| 24.10. | Citi erhöht Kursziel für Arcus Biosciences auf 46 US-Dollar und behält Kaufempfehlung bei | 4 | Investing.com Deutsch | ||
| 24.10. | BofA hält an neutraler Einschätzung für Arcus Biosciences fest | 2 | Investing.com Deutsch | ||
| 21.10. | Neutrale Bewertung für Arcus Biosciences-Aktien vor Datenveröffentlichung | 2 | Investing.com Deutsch | ||
| 21.10. | Where Arcus Biosciences Stands With Analysts | 1 | Benzinga.com | ||
| 10.10. | Arcus Biosciences (NYSE:RCUS) Stock Price Down 5.1% - Here's What Happened | 4 | MarketBeat | ||
| 09.10. | Arcus Biosciences to Present First Clinical Data from ARC-20 Study at the 2024 EORTC-NCI-AACR Symposium | 322 | Business Wire | Data from the 100mg expansion cohort of ARC-20, a Phase 1/1b study of casdatifan in clear cell renal cell carcinoma (ccRCC), will be presented in an oral plenary session by Dr. Toni Choueiri... ► Artikel lesen | |
| 03.10. | Arcus Biosciences (NYSE:RCUS) Rating Reiterated by Wedbush | 3 | MarketBeat | ||
| 03.10. | Demystifying Arcus Biosciences: Insights From 4 Analyst Reviews | 4 | Benzinga.com | ||
| 28.08. | Arcus Biosciences obtains loan facility with Hercules Capital worth $250m | 23 | Pharmaceutical Technology | ||
| 27.08. | Arcus Biosciences secures $250 million loan facility | 1 | Investing.com |
Seite:
1 2 Weiter >>
31 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EPIGENOMICS | 1,570 | 0,00 % | EQS-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß § 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: Epigenomics AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Epigenomics AG: Vorabbekanntmachung über die... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,356 | +0,85 % | Defence Therapeutics Inc.: Defence Provides Update on Delivery of AGSM Proxy Materials | Vancouver, British Columbia--(Newsfile Corp. - December 2, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company... ► Artikel lesen | |
| GINKGO BIOWORKS | 10,300 | +0,98 % | Ginkgo Bioworks CFO Mark Dmytruk veräußert Aktien im Wert von 7.146 US-Dollar | ||
| RECURSION PHARMACEUTICALS | 8,265 | 0,00 % | Recursion Pharmaceuticals, Inc.: Recursion announces first patient dosed in Phase 1/2 clinical study of REC-1245, a potential first-in-class, RBM39 degrader for Biomarker-Enriched Solid Tumors and Lymphoma | First program to result from end-to-end use of OS to identify a novel target and new chemical matter, which moved from target ID to IND enabling studies in under 18 months with ~200 compounds synthesizedREC-1245... ► Artikel lesen | |
| BEAM THERAPEUTICS | 27,490 | +2,92 % | Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology ... | NHP Data Showed CD117 Monoclonal Antibody (mAb) Conditioning Successfully Achieved Long-term Engraftment of Base-edited Hematopoietic Stem Cells and Induced Robust Levels of Hemoglobin F mAb Dosing... ► Artikel lesen | |
| ONCOLYTICS BIOTECH | 0,835 | +0,60 % | Oncolytics Biotech Inc.: Oncolytics Biotech Reports Completion of Initial Safety Phase Enrollment for GOBLET Trial's New Pancreatic Cancer Cohort | Early safety and tolerability results from six randomized patients support continued enrollment of pelareorep combined with modified FOLFIRINOX, with or without... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 18,830 | 0,00 % | Arcturus Therapeutics Holdings Inc.: Arcturus Therapeutics to Present at Jefferies London Healthcare Conference | Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities... ► Artikel lesen | |
| ASSERTIO | 0,938 | -0,38 % | Assertio Holdings, Inc.: Assertio Reports Third Quarter 2024 Financial Results | Third Quarter Total Net Product Sales of $28.7 Million Rolvedon Net Product Sales of $15.0 Million Cash and Short-Term Investments of $88.6 Million LAKE FOREST, Ill., Nov. 11, 2024 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| SIGA TECHNOLOGIES | 6,945 | -0,36 % | SIGA Technologies - TPOXX chalks up another DoD contract win | SIGA Technologies announced another contract win with the US Department of Defense (DoD), which is for the procurement of c $9m in TPOXX. This is the third DoD contract win in roughly three years for... ► Artikel lesen | |
| ADMA BIOLOGICS | 19,010 | 0,00 % | Looking Into ADMA Biologics' Recent Short Interest | ||
| VIR BIOTECHNOLOGY | 8,720 | 0,00 % | Vir Biotechnology EVP Vanina de Verneuil verkauft Aktien im Wert von 624 US-Dollar | ||
| VERVE THERAPEUTICS | 7,180 | 0,00 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on November 29,... ► Artikel lesen | |
| TRAVERE THERAPEUTICS | 17,800 | +0,56 % | Travere Therapeutics, Inc.: Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that on November 10, 2024, the Compensation Committee of its Board of Directors granted inducement... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 18,670 | 0,00 % | Here's Why Summit Therapeutics Stock Price Rose 6% on Friday | ||
| ARVINAS | 25,065 | 0,00 % | Arvinas Inc.: Arvinas Reports Third Quarter 2024 Financial Results and Provides Corporate Update | - On track to report topline data from Phase 3 VERITAC-2 trial in 4Q24 or 1Q25 - - Initial clinical data from Phase 1/2 TACTIVE-U sub-study of abemaciclib in combination with vepdegestrant to be presented... ► Artikel lesen |
ARCUS BIOSCIENCES INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 17,480 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ARCUS BIOSCIENCES INC finden Sie auf Wallstreet Online.
